ABBOTT LABORATORIES
Abbott is a healthcare company that discovers, develops, manufactures, and sells healthcare products worldwide. It has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its branded generic pharmaceuticals are marketed and sold outside the United States in emerging markets, while its diagnostic systems and tests, nutritional products, and medical devices are sold worldwide. Abbott’s products include medicines and biosimilars; laboratory, molecular, and point-of-care diagnostic systems and tests; infant, adult, and enteral nutrition products; and cardiovascular, diabetes care, continuous glucose monitoring, and neuromodulation devices. It sells to consumers, healthcare professionals and facilities, laboratories, wholesalers, distributors, retailers, and government agencies, using direct sales and distributors depending on the product and market. Abbott is headquartered in Abbott Park, Illinois.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ABT in the last 30 days.
See all $ABT insider activity →Boston Scientific, Abbott, Nevro, and Medtronic face lawsuits over spinal cord stimulators, alleging patient harm. The global market is growing at 6.8% CAGR, with Medtronic holding a 29.8% US market share. Lawsuits stem from FDA recalls and reports of malfunctions, with Abbott disputing allegations. Trials are not yet scheduled.
Abbott Laboratories (ABT) presented positive clinical trial results for two cardiovascular devices at a conference. The Amulet 360 LAA Occluder showed 96.3% complete closure in patients, with low complication rates. The SonicForce System achieved 97% procedural success in treating calcified coronary arteries. ABT shares rose 2.55% to $108.91.
Abbott (NYSE: ABT) reported positive 30-day results from its TECTONIC study of the investigational SonicForce Coronary IVL System, which met safety and effectiveness endpoints. The study showed a 0.3% target lesion failure rate and 97% procedural success in treating severe coronary calcification. The system uses acoustic pressure waves to crack calcium buildup in arteries, potentially expanding Abbott's portfolio of cardiovascular devices.
Over the past 7 days, AlphAI's AI scored 9 news stories mentioning ABT (ABBOTT LABORATORIES). Coverage has skewed bullish: 6 bullish, 0 neutral, and 3 bearish.
Recent ABT coverage spans financial news, technology and regulation.
Legal exposure could negatively affect the share price.
The data suggest Abbott's cardiovascular device portfolio is gaining clinical validation, which could boost investor confidence.
Positive trial data may boost Abbott's stock on expectations of future FDA approval and expanded coronary device portfolio.
Negative pressure as market prices in safety concerns and potential recall.
Guidance cut may depress the stock.
AlphAI scores every news story that mentions ABT with an AI model for sentiment and relevance, and aggregates insider trades from ABBOTT LABORATORIES's SEC EDGAR Form 4 filings. Figures refresh continuously.
Boston Scientific, Abbott, Nevro, and Medtronic face lawsuits over spinal cord stimulators, alleging patient harm. The global market is growing at 6.8% CAGR, with Medtronic holding a 29.8% US market share. Lawsuits stem from FDA recalls and reports of malfunctions, with Abbott disputing allegations. Trials are not yet scheduled.
Abbott Laboratories (ABT) presented positive clinical trial results for two cardiovascular devices at a conference. The Amulet 360 LAA Occluder showed 96.3% complete closure in patients, with low complication rates. The SonicForce System achieved 97% procedural success in treating calcified coronary arteries. ABT shares rose 2.55% to $108.91.
Abbott (NYSE: ABT) reported positive 30-day results from its TECTONIC study of the investigational SonicForce Coronary IVL System, which met safety and effectiveness endpoints. The study showed a 0.3% target lesion failure rate and 97% procedural success in treating severe coronary calcification. The system uses acoustic pressure waves to crack calcium buildup in arteries, potentially expanding Abbott's portfolio of cardiovascular devices.
DRAP issued alerts about counterfeit flu vaccines in Pakistan, falsely labeled as Influvac Tetra (Abbott) and Vaxigrip Tetra (Sanofi). Both companies confirmed the vaccines are fake. DRAP warned of serious health risks and urged reporting of suspicious batches. Provincial authorities were directed to seize affected stock.
Analysts made notable calls this week. D.A. Davidson upgraded Broadcom (AVGO) to Buy with a $400 price target, citing AI-related growth prospects. William Blair downgraded Moderna (MRNA) to Market Perform due to valuation concerns. Argus downgraded Abbott (ABT) to Hold after its reduced growth outlook. Jefferies upgraded Rivian (RIVN) to Buy, citing progress in margins and execution. GF Securities raised AMD's (AMD) price target to $720, expecting strong data center growth.
EY's 2026 medtech report highlights record M&A, spinoffs, and declining valuations. M&A reached $130B, driven by large deals like Abbott's $21B acquisition of Exact Sciences. Spinoffs continued, including Medtronic's MiniMed. Valuations fell 10% to $1.58T market cap.
Abbott (NYSE: ABT) launched the CROWN-MV trial to test its Cephea mitral valve replacement device for patients ineligible for surgery or repair. The study aims to enroll up to 585 participants and will evaluate the safety and effectiveness of the investigational device. Early feasibility study results will be presented at TCT 2026. The Cephea system offers a minimally invasive option for treating mitral valve disease, complementing Abbott's existing portfolio of heart therapies.
iShares U.S. Medical Devices ETF (IHI) added $79.7M in assets, increasing positions in 48 holdings. Largest buys included ABT ($14.1M), ISRG ($12.4M), and MDT ($9.0M). IHI has $3.64B in AUM, a 0.37% expense ratio, and a YTD return of -11.92%.
Abbott Laboratories (ABT) experienced $23.9 million in net ETF buying on Monday, with 25 ETFs purchasing shares and 9 selling. The largest buyers were IHI, XLV, and DFLV. ABT's market cap is $178.4 billion, with a P/E of 38.06 and a dividend yield of 2.59%.
Medtronic (MDT), Abbott Laboratories (ABT), and Johnson & Johnson (JNJ) have long dividend growth streaks. MDT yields 2.95%, ABT 2.46%, and JNJ 2.0%. MDT's Q1 revenue rose 13.7%, while ABT and JNJ are restructuring. All pay out ~50% of earnings, with strong free cash flow.
